These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 20691481)
1. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. Bortnick B; El-Khalili N; Banov M; Adson D; Datto C; Raines S; Earley W; Eriksson H J Affect Disord; 2011 Jan; 128(1-2):83-94. PubMed ID: 20691481 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Liebowitz M; Lam RW; Lepola U; Datto C; Sweitzer D; Eriksson H Depress Anxiety; 2010 Oct; 27(10):964-76. PubMed ID: 20734365 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845 [TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Katila H; Mezhebovsky I; Mulroy A; Berggren L; Eriksson H; Earley W; Datto C Am J Geriatr Psychiatry; 2013 Aug; 21(8):769-84. PubMed ID: 23567397 [TBL] [Abstract][Full Text] [Related]
5. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. Bauer M; El-Khalili N; Datto C; Szamosi J; Eriksson H J Affect Disord; 2010 Dec; 127(1-3):19-30. PubMed ID: 20884063 [TBL] [Abstract][Full Text] [Related]
6. Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate. Sheehan DV; Locklear J; Svedsäter H; Datto C Int Clin Psychopharmacol; 2012 Sep; 27(5):239-48. PubMed ID: 22859063 [TBL] [Abstract][Full Text] [Related]
7. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Katzman MA; Brawman-Mintzer O; Reyes EB; Olausson B; Liu S; Eriksson H Int Clin Psychopharmacol; 2011 Jan; 26(1):11-24. PubMed ID: 20881846 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Merideth C; Cutler AJ; She F; Eriksson H Int Clin Psychopharmacol; 2012 Jan; 27(1):40-54. PubMed ID: 22045039 [TBL] [Abstract][Full Text] [Related]
9. Quetiapine XR: current status for the treatment of major depressive disorder. Pae CU; Sohi MS; Seo HJ; Serretti A; Patkar AA; Steffens DC; Masand PS Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1165-73. PubMed ID: 20307622 [TBL] [Abstract][Full Text] [Related]
10. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941 [TBL] [Abstract][Full Text] [Related]
11. A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned. Cutler AJ; Tran-Johnson T; Kalali A; Aström M; Brecher M; Meulien D Psychopharmacol Bull; 2010; 43(4):37-69. PubMed ID: 21240151 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels. Montgomery SA; Altamura AC; Katila H; Datto C; Szamosi J; Eriksson H Int Clin Psychopharmacol; 2014 Mar; 29(2):93-105. PubMed ID: 24162081 [TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies. Meulien D; Huizar K; Brecher M Hum Psychopharmacol; 2010 Mar; 25(2):103-15. PubMed ID: 20196185 [TBL] [Abstract][Full Text] [Related]
14. Extended release quetiapine fumarate in patients with major depressive disorder: suicidality data from acute and maintenance studies. Weisler R; Montgomery SA; Earley WR; Szamosi J; Eriksson H J Clin Psychiatry; 2014 May; 75(5):520-7. PubMed ID: 24816198 [TBL] [Abstract][Full Text] [Related]
15. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791 [TBL] [Abstract][Full Text] [Related]
16. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study. Riesenberg RA; Baldytcheva I; Datto C Clin Ther; 2012 Nov; 34(11):2202-11. PubMed ID: 23059166 [TBL] [Abstract][Full Text] [Related]
17. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study. Lindenmayer JP; Brown D; Liu S; Brecher M; Meulien D Psychopharmacol Bull; 2008; 41(3):11-35. PubMed ID: 18779774 [TBL] [Abstract][Full Text] [Related]